Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3493 - Toxicity and efficacy of flat-dosed versus body-surface area (BSA)-dosed capecitabine


09 Sep 2017


Poster display session


Cytotoxic Therapy;  Colon and Rectal Cancer


Femke Man


Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393


F.M. Man1, G.D. Veerman1, E. Oomen-De Hoop1, E. Meerten1, T. van Gelder2, R.H.J. Mathijssen1

Author affiliations

  • 1 Medical Oncology, Erasmus MC Cancer Institute, 3015 CE - Rotterdam/NL
  • 2 Hospital Pharmacy, Erasmus MC, 3015 CE - Rotterdam/NL


Abstract 3493


Capecitabine (cape) is a pro-drug for the cytotoxic agent 5-fluorouracil and widely used in the treatment of colorectal cancer. In general, cape is dosed on body surface area (BSA), despite all drawbacks of this dosing strategy. In this study, toxicity and efficacy of flat-dosed cape (i.e. without adjustments for body size) was analysed, and compared to BSA-dosed cape.


All patients treated with cape at our center between 2003-2015 were included when they had been treated with flat-dosed cape and no prior treatment with fluoropyrimidines. Data on adverse events and survival was collected. Cape-specific toxicity (CStox) was defined as toxicity grade for diarrhea ≥ 3, hand-foot syndrome ≥ 2 and neutropenia ≥ 2. Clinical relevant toxicity (CRtox) consisted of hospital admission, dose delay, reduction or discontinuation. Patients were divided per treatment in 3 groups based on BSA-quartiles: lowest 25%, middle 50% and highest 25%, corrected for sex. Toxicity was compared using the X2-test and binary logistic regression analysis. Survival analysis was done by the Kaplan-Meier method.


Among 1952 evaluated patients; 1055 patients were included (60% male). Three regimes were evaluated: cape-radiotherapy (CRT, n = 769), cape-oxaliplatin (CAPOX, n = 189) and cape monotherapy (MONO, n = 97). The mean dose of flat-dosed cape was 7.1% lower compared to BSA-dosed cape (p  0.05), for CRT there was a difference in CStox (p = 0.009) and CRtox (p = 0.014). Corrected for sex, age and renal function, only in the CRT group BSA predicted CStox (OR: 0.248, 95% CI: 0.072-0.857, p = 0.028) and CRtox (OR: 0.246, 95% CI: 0.083-0.727, p = 0.011). Survival analyses for CAPOX and CRT showed no differences between BSA-groups and median survival was comparable to literature.


Flat-dosed cape is safe in CAPOX and MONO. Only in CRT, BSA is predictive for CStox and CRtox. No survival differences could be identified in subgroups. Therefore, flat-dosed cape is a safe and effective dosing strategy in regimens without RT.

Clinical trial identification

Legal entity responsible for the study

Department of Medical Oncology, Erasmus MC Cancer Institute




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.